Thulasee Jose1, Darrell R Schroeder2, David O Warner1. 1. Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA. 2. Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Abstract
INTRODUCTION: Continued cigarette smoking is a critical determinant of outcome in oncology patients, but how the separate events of cancer diagnosis, cancer treatment, and completion of treatment affect smoking behavior in cancer survivors is unknown. This study described such changes, hypothesizing that they would be more pronounced for smoking-related cancers. METHODS: The Cancer Patient Tobacco Use Questionnaire (CTUQ) was sent to every cancer patient ≥ 18 y old scheduled for outpatient visits at the Mayo Clinic Cancer Center with a current or former history of tobacco use. RESULTS: From September 2019 to September 2020, 33,831 patients received the CTUQ, and 20,818 (62%) responded. Of the 3007 current smokers analyzed, 34% quit at diagnosis; those with smoking-related cancers were more likely to quit (40% vs. 29%, respectively, p < .001). Among those who did not quit at diagnosis, 31% quit after starting cancer treatment, and those with smoking-related cancers were more likely to quit (35% and 28%, respectively, p = .002) Among those who had quit before the completion of treatment, 13% resumed smoking after treatment ended. In multivariable analysis, patients with smoking-related cancers were more likely to report 30-d point prevalence abstinence from pre-diagnosis to the completion of treatment (adjusted OR 1.98 [95% CI 1.65, 2.36], p < .001). CONCLUSIONS: Both cancer diagnosis and treatment prompt smoking abstinence, with most maintaining abstinence after treatment is completed. Those with smoking-related cancers are more likely to quit. These results emphasize the need to provide access to tobacco treatment services that can further support cancer patients who smoke. IMPLICATIONS: Approximately one-third of cancer patients who smoke quit smoking at the time of diagnosis, an additional one-third of patients who had not yet quit did so at the initiation of treatment, and most sustained this abstinence after treatment completion. Patients with smoking-related cancers are more likely to quit. Thus, there are multiple opportunities within the cancer care continuum to intervene and support quit attempts or continued abstinence.
INTRODUCTION: Continued cigarette smoking is a critical determinant of outcome in oncology patients, but how the separate events of cancer diagnosis, cancer treatment, and completion of treatment affect smoking behavior in cancer survivors is unknown. This study described such changes, hypothesizing that they would be more pronounced for smoking-related cancers. METHODS: The Cancer Patient Tobacco Use Questionnaire (CTUQ) was sent to every cancer patient ≥ 18 y old scheduled for outpatient visits at the Mayo Clinic Cancer Center with a current or former history of tobacco use. RESULTS: From September 2019 to September 2020, 33,831 patients received the CTUQ, and 20,818 (62%) responded. Of the 3007 current smokers analyzed, 34% quit at diagnosis; those with smoking-related cancers were more likely to quit (40% vs. 29%, respectively, p < .001). Among those who did not quit at diagnosis, 31% quit after starting cancer treatment, and those with smoking-related cancers were more likely to quit (35% and 28%, respectively, p = .002) Among those who had quit before the completion of treatment, 13% resumed smoking after treatment ended. In multivariable analysis, patients with smoking-related cancers were more likely to report 30-d point prevalence abstinence from pre-diagnosis to the completion of treatment (adjusted OR 1.98 [95% CI 1.65, 2.36], p < .001). CONCLUSIONS: Both cancer diagnosis and treatment prompt smoking abstinence, with most maintaining abstinence after treatment is completed. Those with smoking-related cancers are more likely to quit. These results emphasize the need to provide access to tobacco treatment services that can further support cancer patients who smoke. IMPLICATIONS: Approximately one-third of cancer patients who smoke quit smoking at the time of diagnosis, an additional one-third of patients who had not yet quit did so at the initiation of treatment, and most sustained this abstinence after treatment completion. Patients with smoking-related cancers are more likely to quit. Thus, there are multiple opportunities within the cancer care continuum to intervene and support quit attempts or continued abstinence.
Authors: Heather D'Angelo; Betsy Rolland; Robert Adsit; Timothy B Baker; Marika Rosenblum; Danielle Pauk; Glen D Morgan; Michael C Fiore Journal: Cancer Prev Res (Phila) Date: 2019-09-03
Authors: J Lee Westmaas; Christina C Newton; Victoria L Stevens; W Dana Flanders; Susan M Gapstur; Eric J Jacobs Journal: J Clin Oncol Date: 2015-04-20 Impact factor: 44.544
Authors: Richard S Matulewicz; Ramsankar Basak; Ibardo Zambrano; Bianca A Dearing; Daniel Schatz; Omar El Shahawy; Scott Sherman; Marc A Bjurlin Journal: J Urol Date: 2020-12-21 Impact factor: 7.450
Authors: M Shayne Gallaway; Rebecca Glover-Kudon; Behnoosh Momin; Mary Puckett; Natasha Buchanan Lunsford; Kathleen R Ragan; Elizabeth A Rohan; Stephen Babb Journal: J Cancer Surviv Date: 2019-01-05 Impact factor: 4.442
Authors: Martina Taborelli; Luigino Dal Maso; Antonella Zucchetto; Elda Lamaj; Paolo De Paoli; Antonino Carbone; Diego Serraino Journal: Tumori Date: 2021-04-20 Impact factor: 2.098
Authors: Richard S Matulewicz; Jeffrey C Bassett; Lorna Kwan; Scott E Sherman; William J McCarthy; Christopher S Saigal; John L Gore Journal: Cancer Date: 2021-12-07 Impact factor: 6.860
Authors: Paul M Cinciripini; Maher Karam-Hage; George Kypriotakis; Jason D Robinson; Vance Rabius; Diane Beneventi; Jennifer A Minnix; Janice A Blalock Journal: JAMA Netw Open Date: 2019-09-04